The DEPOSEIN - how meaningful was the benefit from intrathecal chemotherapy? by Le Rhun, Emilie et al.








The DEPOSEIN - how meaningful was the benefit from intrathecal
chemotherapy?
Le Rhun, Emilie ; Weller, Michael ; Le Deley, Marie Cecile
DOI: https://doi.org/10.1093/neuonc/noaa195






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Le Rhun, Emilie; Weller, Michael; Le Deley, Marie Cecile (2020). The DEPOSEIN - how meaningful was
the benefit from intrathecal chemotherapy? Neuro-Oncology, 22(11):1710-1711.
DOI: https://doi.org/10.1093/neuonc/noaa195
 1 
The DEPOSEIN – how meaningful was the benefit from intrathecal chemotherapy? 
 
We appreciate the interest of Shivaprasad and colleagues in the DEPOSEIN trial 1. 
Our colleagues (i) address imbalances between study groups summarized in their 
Table 1 and (ii) challenge the clinical relevance of the differences in outcome 
between groups. 
Imbalances in study arms are inevitable in a relatively small study and in a highly 
complex clinical setting such as leptomeningeal metastasis. As stated in the 
CONSORT statement 2, any differences in baseline characteristics are, however, the 
result of chance rather than bias. As recommended, we have not provided 
significance tests of baseline differences, which would only assess the probability 
that observed baseline differences could have occurred by chance. In the current 
context, the only significant difference would concern the HER2 status (p=0.045), as 
the other p-values are p=0.20 for “poor differentiation”, p=0.42 for “T1-T3” versus 
“T4”, p=0.50 for “N0-N1” versus “N2-N3”, p=0.25 for “prior CNS radiotherapy”, 
p=0.13 for “brain metastasis”, p=0.35 for ECOG 0 versus 1 versus 2-3 and p=0.14 
for neurological deficit “no” versus “major” versus “other”. Also, imbalances per se 
are not a main concern unless there is clear evidence of imbalance of a prognostic 
factor favoring one study group. This remains to be clarified for HER2 status for 
which the imbalance was also moderate at best, but preliminary evidence suggests 
that this imbalance favored the control arm 3. 
Our colleagues suspect “flawed concealment of the allocation sequence”. The 
randomization list was not known by the investigators, but only by the sponsor’s 
Research Unit staff, which is certified ISO9001 and has been successfully audited by 
the French regulatory authority. Lastly, we performed a prespecified sensitivity 
 2 
analysis, adjusting for potential confounding factors (ECOG performance status at 
leptomeningeal metastasis diagnosis, number of prior lines of systemic treatment, 
HER-2 status, and positivity of CSF cytology at leptomeningeal metastasis at 
diagnosis). The estimated magnitude of treatment effect was even larger in the 
adjusted analysis.  
We had rather extensively discussed the limitations of the DEPOSEIN trial in the 
original report. Yet, it remains the only randomized trial in this setting for many years. 
We had acknowledged that the benefit in progression-free survival may be of 
moderate overall clinical relevance, but leptomeningeal metastasis-related 
progression-free survival remains a meaningful outcome parameter to assess benefit 
of a local treatment, and quality of life assessment supported our conclusion. 
Furthermore, we believe that our results support continued exploration of the 
subarachnoid space as an important compartment for therapeutic intervention, using 
better drugs than cytarabine in molecularly enriched patient populations. 
Finally, clinical trials should be judged by the state of the science and knowledge 
when they were designed and conducted. Undoubtedly, future trials in 
leptomeningeal metastasis might benefit from the challenges and shortcomings 
experienced during the conduct and analysis of DEPOSEIN. 
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